Comprehensive registry of esophageal cancer in Japan, 2015
Masayuki Watanabe, Yasushi Toh, Ryu Ishihara, Koji Kono, Hisahiro Matsubara, Tatsuya Miyazaki, Masaru Morita, Kentaro Murakami, Kei Muro, Hodaka Numasaki, Tsuneo Oyama, Hiroshi Saeki, Koji Tanaka, Takahiro Tsushima, Masaki Ueno, Takashi Uno, Toshiyuki Yoshio, Shiyori Usune, Arata Takahashi, Hiroaki Miyata
Abstract
BACKGROUND: The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes of patients who underwent any treatment during 2015 in Japan. METHODS: edition by JES and the TNM classification by the Union of International Cancer Control (UICC) for cancer staging. RESULTS: A total of 9368 cases were registered from 355 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 86.7% and 7.4%, respectively. The 5-year survival rates of patients treated by endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.2%, 33.5%, 24.2%, and 59.9%, respectively. Esophagectomy was performed in 5172 cases. Minimally invasive approaches were selected for 60.6%, and 54.4% underwent thoracoscopic esophagectomy. The operative mortality (within 30 days after surgery) was 0.79% and the hospital mortality was 2.3%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system because pStage IV included the patients with supraclavicular lymph node metastasis (M1 LYM). CONCLUSION: We hope this report improves all aspects of diagnosing and treating esophageal cancer in Japan.